Abstract
It is well known that tumor formation arises from the imbalance between cell death and proliferation. For many years, cancer research has engaged an important part of its efforts to find new therapeutic strategies based on cell death induction. One of the predominant ways to kill tumor cells is to trigger apoptosis by chemotherapy. However tumor responsiveness to chemotherapy is dependent on different biological factors including cancer types, genetics and pharmacogenetics. Although, molecular mechanisms involved in chemotherapy-induced apoptosis are diverse and depend on celltype and drugs used, a common pathway leading to tumor cell death has been shown to implicate the generation of a simple cellular sphingolipid, ceramide. Ceramide is released by the activity of neutral or acidic sphingomyelinases or de novo synthesis during treatment with chemotherapy. This review in particular focuses on enzymes involved in chemotherapyinduced cell death such as neutral or acidic sphingomyelinases and ceramide synthases, the role of ceramide in cellular effects of chemotherapy at the plasma membrane or the mitochondria and the induction of cell death by ceramide. It also includes recent advances on novel patented sphingolipid compounds and cancer therapeutic strategies based on ceramide release.
Keywords: Ceramide, sphingomyelinase, chemotherapy, ceramide synthase, apoptosis, Anticancer Drugs, MITOCHONDRIA, cell growth, gangliosides
Recent Patents on Anti-Cancer Drug Discovery
Title: Ceramide in Chemotherapy of Tumors
Volume: 6 Issue: 3
Author(s): Marie-Therese Dimanche-Boitrel, Amelie Rebillard and Erich Gulbins
Affiliation:
Keywords: Ceramide, sphingomyelinase, chemotherapy, ceramide synthase, apoptosis, Anticancer Drugs, MITOCHONDRIA, cell growth, gangliosides
Abstract: It is well known that tumor formation arises from the imbalance between cell death and proliferation. For many years, cancer research has engaged an important part of its efforts to find new therapeutic strategies based on cell death induction. One of the predominant ways to kill tumor cells is to trigger apoptosis by chemotherapy. However tumor responsiveness to chemotherapy is dependent on different biological factors including cancer types, genetics and pharmacogenetics. Although, molecular mechanisms involved in chemotherapy-induced apoptosis are diverse and depend on celltype and drugs used, a common pathway leading to tumor cell death has been shown to implicate the generation of a simple cellular sphingolipid, ceramide. Ceramide is released by the activity of neutral or acidic sphingomyelinases or de novo synthesis during treatment with chemotherapy. This review in particular focuses on enzymes involved in chemotherapyinduced cell death such as neutral or acidic sphingomyelinases and ceramide synthases, the role of ceramide in cellular effects of chemotherapy at the plasma membrane or the mitochondria and the induction of cell death by ceramide. It also includes recent advances on novel patented sphingolipid compounds and cancer therapeutic strategies based on ceramide release.
Export Options
About this article
Cite this article as:
Dimanche-Boitrel Marie-Therese, Rebillard Amelie and Gulbins Erich, Ceramide in Chemotherapy of Tumors, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (3) . https://dx.doi.org/10.2174/157489211796957838
DOI https://dx.doi.org/10.2174/157489211796957838 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Near Infrared Receptor-Targeted Nanoprobes for Early Diagnosis of Cancers
Current Medicinal Chemistry T11TS/SLFA-3 Differentially Regulate the Population of Microglia and Brain Infiltrating Lymphocytes to Reduce Glioma by Modulating Intrinsic Bcl-2 Expression rather than p53
Central Nervous System Agents in Medicinal Chemistry The Urokinase Receptor Interactome
Current Pharmaceutical Design Meet Our Associate Editorial Board Member
Current Drug Delivery Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Shaping Tumor Microenvironment for Improving Nanoparticle Delivery
Current Drug Metabolism Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy Patient-Specific Alpha-Particle Dosimetry
Current Radiopharmaceuticals Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design Drug Delivery Across the Blood-Brain Barrier
Current Drug Delivery 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry The Hedgehog Knows Many Tricks
Current Drug Targets Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry Network Pharmacology of Glioblastoma
Current Drug Discovery Technologies Glioma Targeting and Anti-glioma Effect of Interleukin 13 Peptide and RGD Peptide Dual Functionalized Nanoparticles
Current Pharmaceutical Biotechnology